Gland Pharma (NSE:GLAND) Other Stockholders Equity: ₹103,415 Mil (As of Mar. 2026)


NSE:GLAND Gland Pharma Ltd NSE:GLAND
86 GF Score
Price ₹2,462.30
GF Value ₹2,132.00
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Gland Pharma Other Stockholders Equity?

Gland Pharma NSE:GLAND +0.66% 86 Other Stockholders Equity is ₹103,415 Mil as of Mar. 2026. GuruFocus rates NSE:GLAND with a GF Score™ of 86/100 and a GF Value™ of ₹2,132.00 (Modestly Overvalued). The stock has 7 warning signs investors should review.

Gland Pharma's Other Stockholders Equity for the quarter that ended in Mar. 2026 was ₹103,415 Mil.

Gland Pharma's quarterly Other Stockholders Equity declined from Sep. 2025 (₹95,461 Mil) to Dec. 2025 (₹0 Mil) but then increased from Dec. 2025 (₹0 Mil) to Mar. 2026 (₹103,415 Mil).

Gland Pharma's annual Other Stockholders Equity increased from Mar. 2024 (₹-130 Mil) to Mar. 2025 (₹410 Mil) and increased from Mar. 2025 (₹410 Mil) to Mar. 2026 (₹103,415 Mil).

Gland Pharma Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Gland Pharma's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gland Pharma Other Stockholders Equity Chart

Gland Pharma Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only 81.10 -49.03 -130.49 410.06 103,414.74

Gland Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 410.06 0.00 95,461.27 0.00 103,414.74
NSE:GLAND
86GF Score
Gland Pharma Ltd NSE:GLAND
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gland Pharma Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of ₹103,415 Mil mean?
Gland Pharma (NSE:GLAND) has a Other Stockholders Equity of ₹103,415 Mil as of Mar. 2026. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Gland Pharma and its competitors.
Is Gland Pharma's Other Stockholders Equity too high?
Gland Pharma's current Other Stockholders Equity is ₹103,415 Mil. Overall, Gland Pharma has a GF Score™ of 86/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Gland Pharma's Other Stockholders Equity compare to ZTS and UTHR?
Gland Pharma's Other Stockholders Equity of ₹103,415 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Drug Manufacturers company?
A good Other Stockholders Equity depends on the Drug Manufacturers industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on Gland Pharma and its competitors. Gland Pharma's current Other Stockholders Equity is ₹103,415 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gland Pharma stock overvalued right now?
Based on GuruFocus' analysis, Gland Pharma (NSE:GLAND) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹2,132.00, compared to a current price of ₹2,462.30 — trading 15.5% above its estimated fair value. The current Other Stockholders Equity is ₹103,415 Mil. Gland Pharma's overall GF Score™ is 86/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For Gland Pharma (NSE:GLAND), the current Other Stockholders Equity is ₹103,415 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gland Pharma (NSE:GLAND) Overvalued in 2026?

Based on GuruFocus' analysis, Gland Pharma stock appears to be overvalued. The current stock price of ₹2,462.30 is trading 15.5% above its estimated GF Value™ of ₹2,132.00. GuruFocus considers Gland Pharma to be Modestly Overvalued.

Key valuation signals for NSE:GLAND:

  • Other Stockholders Equity: ₹103,415 Mil
  • GF Value™: ₹2,132.00 vs. price of ₹2,462.30 (15.5% above fair value)
  • GF Score™: 86/100 with 7 warning signs

No single metric tells the full story. See the NSE:GLAND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Gland Pharma Business Description

Other Exchanges 543245:India
Address TSIIC, Phase - IV, Plot No. 11 and 84, Pashamylaram (V), Patancheru M, Sangareddy District, Hyderabad, TG, IND, 502307
Gland Pharma Ltd is engaged in the development, manufacturing, and marketing of complex injectables. The company's key molecules include Heparin Sodium Injection, Enoxaparin Sodium Injection, Rocuronium Bromide Injection, and Daptomycin Injection, among others. The group is also involved in a vast range of therapeutic categories, including Anti-Infectives, Anesthetics, Anti-Coagulants and their Antidotes, Anti-Malarials, Cardiology, and more, to Hormones and related Drugs, Fertility Supplements, and GnRH Agonists and Antagonists. Geographically, it derives a majority of revenue from the USA, and the rest from Europe, India, Canada, Australia, and other regions.
86GF Score

Get the complete analysis for NSE:GLAND

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,462.30
Price
₹2,132.00
GF Value